EYPT - ピ―シビダ （EyePoint Pharmaceuticals Inc.） ピ―シビダEYPTのチャート
EYPTの企業情報
| symbol | EYPT |
|---|---|
| 会社名 | EyePoint Pharmaceuticals Inc （ピ―シビダ） |
| 分野（sector） | Capital Goods 資本財（工業製品） |
| 産業（industry） | Biotechnology: Laboratory Analytical Instruments |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アイポイント・ファーマシューティカルズ(Eyepoint Pharmaceuticals Inc.)(旧名：pSivida Corp.)は主に慢性眼疾患の治療用の薬物送達製品を開発する。同社は目の裏目の病気の治療のための3つの製品を開発した。後部セグメントブドウ膜炎のためのMedidurは、主要な第III相臨床試験にあるリード製品候補である。糖尿病性黄斑浮腫（DME）のILUVIENは、米国および欧州連合（EU）諸国で販売されている主要ライセンス製品である。また、Retisertを含む。Medidurは、眼の後部に影響を与える慢性非感染性ブドウ膜炎（後部ブドウ膜炎）を治療するように設計される。ILUVIENは、単回注射からDMEの治療を提供する注射可能なマイクロインサートである。Retisertは、後区域ブドウ膜炎の治療を提供するインプラントである。同社の製品開発プログラムは、DurasertとTethadurの2つの技術プラットフォームを利用して、慢性疾患治療薬と生物製剤を提供することに重点を置く。 ピ―シビダは、米国の医薬品会社。目の奥の慢性疾患の治療に焦点を当てた医薬品「Durasert」と「Tethadur」を開発。また、製品候補「Medidur」は、第3相臨床試験段階である。同社の主要製品「ILUVIEN」は、欧州連合(EU)で承認され、米国食品医薬品局(FDA)では承認が保留されている。 EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA. |
| 本社所在地 | 480 Pleasant Street Watertown MA 02472 USA |
| 代表者氏名 | Goran A. Ando ゴラン・アンドド |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 617-926-5000 |
| 設立年月日 | 31868 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 44人 |
| url | www.eyepointpharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/eypt |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -25.12600 |
| 終値（lastsale） | 3.28 |
| 時価総額（marketcap） | 244399517.44 |
| 時価総額 | 時価総額（百万ドル） 250.36050 |
| 売上高 | 売上高（百万ドル） 2.96100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 228.89350 |
| 当期純利益 | 当期純利益（百万ドル） -53.17100 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Eyepoint Pharmaceuticals Inc revenues decreased 61% to $3M. Net loss increased from $18.5M to $53.2M. Revenues reflect United States segment decrease of 62% to $2.9M. Higher net loss reflects Research and Development Expense increase of 12% to $14.9M (expense) General and administrative increase of 3% to $10.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.52 to -$1.15. |
EYPTのテクニカル分析
EYPTのニュース
Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) Short Interest Up 6.6% in October 2019/11/17 19:26:47 Modern Readers
Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) was the recipient of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 5,640,000 shares, an increase of 6.6% from the September 30th total of 5,290,000 shares. Approximately 8.8% of the shares of the stock are short sold. Based on […]
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded to “Hold” at ValuEngine 2019/11/08 06:52:41 Modern Readers
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Friday, ValuEngine reports. Several other equities research analysts have also commented on EYPT. Laidlaw assumed coverage on Eyepoint Pharmaceuticals in a research note on Monday. They set a “buy” rating and a […]
2 Candidates That Could Be the Next Biotech Rockets 2019/10/18 12:31:40 TheStreet
Omeros Corp. and EyePoint Pharmaceuticals are two small biotech companies that each have promising treatments that could send their shares skyward….OMER
EyePoint Pharmaceuticals (EYPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release 2019/07/31 14:36:29 Zacks Investment Research
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eyepoint Pharmaceuticals (EYPT) Investor Presentation - Slideshow 2019/06/06 19:33:13 Seeking Alpha
The following slide deck was published by EyePoint Pharmaceuticals, Inc. in conjunction with this event.
Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) Short Interest Up 6.6% in October 2019/11/17 19:26:47 Modern Readers
Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) was the recipient of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 5,640,000 shares, an increase of 6.6% from the September 30th total of 5,290,000 shares. Approximately 8.8% of the shares of the stock are short sold. Based on […]
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded to “Hold” at ValuEngine 2019/11/08 06:52:41 Modern Readers
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Friday, ValuEngine reports. Several other equities research analysts have also commented on EYPT. Laidlaw assumed coverage on Eyepoint Pharmaceuticals in a research note on Monday. They set a “buy” rating and a […]
2 Candidates That Could Be the Next Biotech Rockets 2019/10/18 12:31:40 TheStreet
Omeros Corp. and EyePoint Pharmaceuticals are two small biotech companies that each have promising treatments that could send their shares skyward….OMER
EyePoint Pharmaceuticals (EYPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release 2019/07/31 14:36:29 Zacks Investment Research
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eyepoint Pharmaceuticals (EYPT) Investor Presentation - Slideshow 2019/06/06 19:33:13 Seeking Alpha
The following slide deck was published by EyePoint Pharmaceuticals, Inc. in conjunction with this event.
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2019 Results - Earnings Call Transcript 2019-05-08
EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2019 Earnings Conference Call May 8, 2019, 08:30 AM ET Company Participants David Price - CFO Nancy Lurker - President and CEO Conference Call Participants Andrew D'Silva - B. Riley FBR Yi Chen - H.C. Wainwright Presentation O…